Additionally, the expression of SMARCA2 influences the expression of Fructose‐1,6‐bisphosphatase 1 (FBP1), and the low expression of FBP1 is related to the clinical stage of bladder cancer, more frequent recurrence, and metastasis. Here, SMARCA2 is linked to urinary bladder cancer.